Acetylator phenotypes in diabetes mellitus.

Area of Science:

• Pharmacogenetics
• Diabetology
• Neurology

Background:

• Diabetic neuropathy is a common complication of diabetes mellitus.
• The rate of drug acetylation, a genetically determined metabolic process, can vary significantly among individuals.
• Understanding genetic factors influencing drug metabolism may offer insights into diabetes complications.

Purpose of the Study:

• To determine the correlation between genetically determined drug acetylation rates (acetylator phenotype) and the development of diabetic neuropathy.
• To compare acetylator phenotype distribution in healthy individuals, type I diabetes, and type II diabetes patients.
• To explore the potential of acetylator phenotype as a genetic marker for type I diabetes.

Main Methods:

• Acetylator phenotype was determined using the Evans method.
• 100 healthy individuals and 160 diabetic patients (80 type I, 80 type II) were included.
• Diabetic neuropathy was diagnosed via clinical neurological examination; electrostimulation was performed in a subset of patients.

Main Results:

• In healthy controls, 44% were fast and 56% were slow acetylators.
• Type I diabetes patients showed a statistically significant predominance of fast acetylators (64%) compared to healthy controls (p < 0.01).
• No significant correlation was identified between diabetic neuropathy and the distribution of acetylator phenotype in diabetic patients.

Conclusions:

• A higher prevalence of fast acetylators was observed in type I diabetes patients compared to the healthy population.
• The study did not find a significant association between acetylator phenotype and the presence of diabetic neuropathy.
• Further prospective research is warranted to investigate the potential of acetylator phenotype as a genetic marker for type I diabetes.